McNicoll, Lewis & Vlak reiterated its Vivus VVUS Buy rating and $16 price target in a research report published today.
In the report, McNicoll, Lewis & Vlak states, "Although FORTRESS will have a greater number of dyads (mother-infant pairs), it will be similar in methodology and design to the Wolters Kluwer study (Exhibit 1). Therefore, we will compare the relative risks and confidence intervals of FORTRESS to that of the Wolters Kluwer data. If these are similar, we believe the FDA and EMEA will conclude that topiramate is not a major teratogen."
Shares of Vivus were trading at $7.36 at the time of posting, down 1.47% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in